Risk for 20-year melanoma-related death increases significantly for patients with primary tumors of 0.8 to 1.0 mm in ...

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have ...

There have been several milestones in my 86 years on Earth: marrying my wife, Pat, (celebrating 53 years in 2025), the births of our daughters and granddaughters, my first day working for the ...

After a Stage 4 cancer diagnosis and a prognosis of 16 months to live, Katie Doble didn’t know whether she should plan her ...

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...

Research has introduced daromun, therapeutic vaccines, and novel combinations for metastatic melanoma, reshaping the ...

Trial remains on track for completion and data readout in the second half of 2025COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

Evaxion Biotech A/S (EVAX), a clinical-stage TechBio company specializing in AI-driven vaccines, has announced the completion of ...